The regulation of mRNA translation is a fundamental branch of post-transcriptional mechanisms, which control gene expression in development and differentiation.^[@bib1]^ Translation of specific mRNAs is under the surveillance of *trans* acting factors that interact with *cis* elements located predominantly in their UTRs.^[@bib2]^ In differentiating erythroid cells hnRNP K regulates translation of specific mRNAs. Post-translational modifications of hnRNP K have been shown to modulate its capacity in regulatory complex formation.^[@bib3],\ [@bib4],\ [@bib5],\ [@bib6]^ Erythroid precursor cells undergo nuclear extrusion and mitochondria degradation in reticulocytes at the terminal step of erythrocyte formation. Mitochondria degradation is initiated by r15-LOX expressed only in mature reticulocytes. HnRNP K silences r15-LOX mRNA translation in premature reticulocytes.^[@bib7],\ [@bib8]^ In late erythroid maturation, translation inhibition is abolished by phosphorylation of Y458 in KH domain 3 that mediates binding to the DICE in the r15-LOX mRNA 3′UTR.^[@bib4],\ [@bib5]^ Additionally, a decreasing hnRNP K level contributes to the release of the silencing complex.^[@bib9]^ Although the function of site-specific phosphorylation in r15-LOX mRNA translation regulation has been elucidated, there is no information about the mechanism of hnRNP K degradation in erythroid differentiation. Here we analyze the degradation of hnRNP K during induced erythroid differentiation of K562 cells to get further insight in its function as a regulator of post-transcriptional control of gene expression. We found that the ubiquitin E3 ligase HDM2, which was shown to ubiquitinate hnRNP K in p53-dependent DNA damage repair^[@bib10]^ is not expressed in K562 cells ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Additionally, we show that hnRNP K is not ubiquitinated in K562 cells and proteasome inhibitors fail to stabilize the protein. Caspases not only catalyze site-specific protein cleavage in apoptosis,^[@bib11]^ but were also shown to be activated in terminal erythroid differentiation,^[@bib12],\ [@bib13],\ [@bib14]^ which is not associated with apoptosis.^[@bib15]^ Interestingly, a specific N-terminal hnRNP K fragment that migrates at 48 kD accumulates during erythroid differentiation. We purified and analyzed this fragment by mass spectrometry and showed that it is a cleavage product of Caspase-3, which is activated during erythroid differentiation in an apoptosis independent manner. Residues D334--G335 were identified as Caspase-3 cleavage site that separates the DICE-binding KH domain 3 from the N-terminal part, which contains critical protein-protein interaction domains.^[@bib5],\ [@bib16],\ [@bib17]^ Thus, Caspase-3 mediated cleavage inactivates hnRNP K as a regulator of r15-LOX mRNA translation.

Results
=======

Cleavage of hnRNP K during erythroid differentiation generates an N-terminal fragment that lacks KH domain 3
------------------------------------------------------------------------------------------------------------

The analysis of proteins involved in r15-LOX mRNA translational control revealed that the level of hnRNP K decreases during erythroid differentiation of K562 cells^[@bib9]^ ([Figure 1a](#fig1){ref-type="fig"}). Interestingly, a specific fragment migrating at about 48 kD in SDS-PAGE was detected when hnRNP K was enriched by immunoprecipitation ([Figure 1a](#fig1){ref-type="fig"}), indicating that a specific protease cleaves the protein. This hnRNP K-derived cleavage product was also detected when K562 cells were treated with puromycin for up to 24 h ([Figure 1b](#fig1){ref-type="fig"}). To characterize the fragment initially, hnRNP K was immunoprecipitated from the extracts of non-treated K562 cells, cells induced for erythroid differentiation or cells treated with puromycin. Western blots of the immunoprecipitated protein were incubated with antibodies that recognize the N-terminus (aa 1--121, \#1) ([Figure 1c](#fig1){ref-type="fig"}, lanes 1--3, [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}, lanes 4--6), an internal peptide (aa 255--272, \#2) ([Figure 1c](#fig1){ref-type="fig"}, lanes 4--6) or the C-terminus (aa 452--464, \#3) ([Figure 1c](#fig1){ref-type="fig"}, lanes 7--9). Antibodies that recognize the N-terminus and the internal peptide, but not the C-terminus detected the immunoprecipitated fragment of about 48 kD and minor smaller fragments ([Figure 1c](#fig1){ref-type="fig"}). For further characterization, the cleavage product was purified from puromycin-treated K562 cells ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}), *in gel* digested with trypsin and analyzed by LC-MS/MS. Identified peptides are shown in bold in the hnRNP K sequence ([Figure 1d](#fig1){ref-type="fig"}). The C-terminal amino acid identified was R326. No peptides corresponding to KH domain 3 that specifically mediates binding to the DICE in the r15-LOX mRNA^[@bib5]^ were detected ([Figure 1d](#fig1){ref-type="fig"}).

Caspase-3 is activated during erythroid differentiation of K562 cells
---------------------------------------------------------------------

Caspases are not only activated in apoptosis,^[@bib11]^ but as well in development and differentiation.^[@bib18]^ It was shown that Caspase-3 is activated in erythroid cell differentiation^[@bib12],\ [@bib13],\ [@bib14]^ and during differentiation of lens fiber cells, neuronal stem cells and skeletal muscle cells (reviewed in Lamkanfi *et al*^[@bib18]^). Therefore, we analyzed whether Caspase-3 becomes activated during sodium-butyrate induced erythroid differentiation of K562 cells. Activation of Caspase-3 was monitored in western blot assays by detection of the p34 precursor cleavage fragment p17.^[@bib19]^ When K562 cells were treated with puromycin for 16 h Caspase-3 was strongly activated ([Figure 2a](#fig2){ref-type="fig"}, lane 7). During erythroid maturation activation of Caspase-3 was also detectable, but to a lower level ([Figure 2a](#fig2){ref-type="fig"}, lanes 2--6). To quantify Caspase-3 activation a luminometric assay was used, which is sensitive to the activity of Caspase-3 and Caspase-7 ([Figure 2b](#fig2){ref-type="fig"}). A contribution of Caspase-7 to the read-out of this assay could be excluded, because Caspase-7 that is readily detectable in MCF-7 cells ([Figure 2a](#fig2){ref-type="fig"}, lane 1) was undetectable in K562 cells ([Figure 2a](#fig2){ref-type="fig"}, lanes 2--7). Caspase-3 activity increases up to 14-fold during induced erythroid differentiation and is enhanced to 22-fold upon puromycin treatment ([Figure 2b](#fig2){ref-type="fig"}). The Caspase-3 inhibitor Ac-DMQD-CHO blocks its activity efficiently ([Figure 2b](#fig2){ref-type="fig"}). Additionally, during erythroid differentiation cleavage of poly-ADP-ribose polymerase 1 (PARP) that is a substrate of both, Caspase-3 and Caspase-7^[@bib20]^ was observed ([Figure 2a](#fig2){ref-type="fig"}, lanes 2--6). To exclude that sodium butyrate induces apoptosis in K562 cells, AnnexinV-FITC and propidium iodide staining was performed ([Figure 2c](#fig2){ref-type="fig"}). A strong increase in the amount of apoptotic cells (AnnexinV-FITC positive) could be observed when cells were treated with puromycin, whereas induction of apoptosis did not occur during erythroid differentiation ([Figure 2c](#fig2){ref-type="fig"}). Caspase-3 activity can be regulated by X-chromosome linked inhibitor of apoptosis protein (XIAP), which was shown to bind and inhibit activated Caspase-3 directly.^[@bib21]^ Noteworthy XIAP expression is high in non-induced K562 cells, but expression drops strongly during erythroid differentiation ([Figure 2a](#fig2){ref-type="fig"}, lanes 2--6), indicating that XIAP is involved in regulation of Caspase-3 activity during erythroid differentiation.

Caspase-3 activity is required for hnRNP K cleavage
---------------------------------------------------

To evaluate a potential role of Caspase-3 in hnRNP K degradation, Caspase-3 expression was reduced by RNA interference (RNAi) in combination with puromycin treatment ([Figure 3a](#fig3){ref-type="fig"}). Puromycin treatment of K562 cells for 16 and 24 h resulted in Caspase-3 activation and hnRNP K cleavage ([Figure 3a](#fig3){ref-type="fig"}, lower panel, lanes 1--3 and [Figure 1b](#fig1){ref-type="fig"}). K562 cells were either mock transfected, transfected with a non-specific control siRNA (ctrl) or two individual siRNAs directed against Caspase-3 (Casp-3 \#1, Casp-3 \#2) ([Figure 3a](#fig3){ref-type="fig"}, lower panel, lanes 4--23). Twenty-four hours *post* transfection cells were exposed to puromycin ([Figure 3a](#fig3){ref-type="fig"}, upper panel and lower panel, lanes 12--15 and 20--23). Knockdown of Caspase-3, results in stabilization of full-length hnRNP K after 16 h of puromycin treatment ([Figure 3a](#fig3){ref-type="fig"}, lower panel, lanes 14 and 15). Additionally, a stabilization of the hnRNP K-derived cleavage product was detected after 24-h puromycin treatment, when full-length hnRNP K was below detection level ([Figure 3a](#fig3){ref-type="fig"}, lower panel, lanes 22 and 23). To recapitulate cleavage of hnRNP K by Caspase-3 *in vitro*, cytoplasmic extract of ctrl or Casp-3 \#1 siRNA transfected K562 cells was prepared after 16 h puromycin treatment ([Figure 3b](#fig3){ref-type="fig"}, left panel). In Caspase-3 knockdown extract, the enzymatic activity was reduced to about 60% compared with extract prepared from ctrl siRNA transfected cells ([Figure 3b](#fig3){ref-type="fig"}, right panel), consistent with the reduction of Caspase-3 ([Figure 3b](#fig3){ref-type="fig"}, left panel). His-hnRNP K was incubated in these extracts to analyze hnRNP K cleavage with an antibody directed against the N-terminal His-tag. Although the hnRNP K cleavage product could be detected when the reaction was performed in cytoplasmic extract from ctrl siRNA transfected cells ([Figure 3c](#fig3){ref-type="fig"}, lane 2), cleavage was strongly reduced in extract prepared from Caspase-3 knockdown cells ([Figure 3c](#fig3){ref-type="fig"}, lane 4). The combination of RNAi against Caspase-3 with the induction of erythroid differentiation did not result in a detectable stabilization of hnRNP K (data not shown), probably because a smaller fraction of Caspase-3 is activated in erythroid differentiation compared with puromycin treatment (compare [Figure 2a](#fig2){ref-type="fig"}, lanes 2--7 and [Figure 3a](#fig3){ref-type="fig"} lower panel, lanes 1--3). When K562 cells were treated with puromycin for 16 or 24 h in the presence of the Caspase-3 inhibitor Ac-DMQD-CHO ([Figure 3d](#fig3){ref-type="fig"}), both hnRNP K and the N-terminal fragment were stabilized ([Figure 3d](#fig3){ref-type="fig"}, lanes 5--7 and 9--11) and the p20 Caspase-3 cleavage intermediate could be detected.^[@bib22]^ In contrast, the proteasome inhibitor MG132 did not stabilize hnRNP K ([Figure 3d](#fig3){ref-type="fig"}, lanes 8 and 12). As a control we monitored PARP cleavage, which was also slightly reduced after 16 h in the presence of 10 μℳ Ac-DMQD-CHO ([Figure 3d](#fig3){ref-type="fig"}, lanes 5--7). During erythroid maturation, Ac-DMQD-CHO mediated Caspase-3 inhibition results in both, hnRNP K and PARP stabilization ([Figure 3e](#fig3){ref-type="fig"}, compare lanes 1--3 and lanes 4--9). The 48 kD hnRNP K cleavage product that could be enriched by immunoprecipitation on day 2 of erythroid maturation (see [Figure 1a](#fig1){ref-type="fig"}) can not be visualized in [Figure 3e](#fig3){ref-type="fig"}, lanes 1--3, due to the detection limit of the antibody (see [Figure 1c](#fig1){ref-type="fig"}). In contrast, treatment with the proteasome inhibitor MG132 that induces apoptosis^[@bib23]^ resulted in cleavage of both PARP and hnRNP K ([Figure 3e](#fig3){ref-type="fig"}, lanes 10--12).

HnRNP K is cleaved by ectopically expressed Caspase-3 in MCF-7 cells
--------------------------------------------------------------------

To further verify hnRNP K as a Caspase-3 substrate we employed the breast cancer cell line MCF-7, which in contrast to K562 cells does express Caspase-7, but not Caspase-3 ([Figure 4a](#fig4){ref-type="fig"}, lanes 1--6).^[@bib24]^ To analyze the effect of Caspase-3 on hnRNP K cleavage, we made use of MCF-7 cells stably transfected with Caspase-3 cDNA (MCF-7(Caspase-3)).^[@bib24]^ Caspase-3 was only detected in K562 and MCF-7(Caspase-3) cells, but not pcDNA3.1 transfected MCF-7 cells (MCF-7(pcDNA3.1)) ([Figure 4a](#fig4){ref-type="fig"}). Puromycin treatment resulted in the activation of Caspase-3 and -7 ([Figure 4a](#fig4){ref-type="fig"}) and induced a strong increase in Caspase activity in extracts of K562 cells and MCF-7(Caspase-3) cells as detected by the enzymatic assay ([Figure 4b](#fig4){ref-type="fig"}). The moderate increase of Caspase activity detected in MCF-7(pcDNA3.1) cells ([Figure 4b](#fig4){ref-type="fig"}) might result from puromycin-mediated Caspase-7 activation ([Figure 4a](#fig4){ref-type="fig"}, lanes 4--6).

The cleavage of PARP and hnRNP K was analyzed in the three cell lines. PARP that is a substrate of several Caspases^[@bib20]^ is cleaved in all cell lines upon puromycin treatment ([Figure 4a](#fig4){ref-type="fig"}). In contrast, hnRNP K cleavage could be detected in K562 cells and in MCF-7(Caspase-3) cells ([Figure 4a](#fig4){ref-type="fig"}, lanes 1--3 and 7--9), but not MCF-7(pcDNA3.1) cells ([Figure 4a](#fig4){ref-type="fig"}, lanes 4--6).

Caspase-3 cleaves hnRNP K C-terminal to D334
--------------------------------------------

The analysis of the N-terminal hnRNP K cleavage product identified a peptide with R326 as the C-terminal residue ([Figure 1d](#fig1){ref-type="fig"}). To characterize the cleavage site of Caspase-3 that strictly cleaves C-terminal to aspartate residues,^[@bib25]^ we generated five N-terminal His-tagged hnRNP K variants with aspartate replaced by glutamate C-terminal of R326 (His-hnRNP K D331E, D334E, D342E, D346E and D350E). The recombinant proteins were incubated in cytoplasmic extract from puromycin-treated K562 cells and analyzed in western blots employing a His-tag antibody ([Figure 5a](#fig5){ref-type="fig"}). The N-terminal fragment could only be detected when His-hnRNP K wt or variants D342E, D346E and D350E were used ([Figure 5](#fig5){ref-type="fig"}, lanes 1, 2 and 7--12). His-hnRNP K D331E and D334E were not cleaved ([Figure 5](#fig5){ref-type="fig"}, lanes 3--6), indicating that the protease recognizes a D-x-x-D motif and cleaves C-terminal to D334 of hnRNP K.

The cleavage of hnRNP K detected in MCF-7(Caspase-3) cells ([Figure 4a](#fig4){ref-type="fig"}) and the mutational analysis ([Figure 5a](#fig5){ref-type="fig"}), strongly indicate that specifically Caspase-3 cleaves hnRNP K. Through the use of recombinant activated Caspase-3 and His-hnRNP K(wt) or His-hnRNP K(D334E) in *in vitro* cleavage assays we wanted to exclude that another enzyme that is activated by Caspase-3 processing acts on hnRNP K ([Figure 5b](#fig5){ref-type="fig"}). The signal of the His-hnRNP K(wt) cleavage product detected in western blots increased when the amount of recombinant Caspase-3 was elevated in the *in vitro* cleavage reaction ([Figure 5b](#fig5){ref-type="fig"}, lanes 1--3), but no cleavage product of His-hnRNP K(D334E) could be detected ([Figure 5b](#fig5){ref-type="fig"}, lanes 4--6). The smaller band that appears when His-hnRNP K(wt) or His-hnRNP K(D334E) were used might represent a non-specific *E.coli* product as it could already be detected when Caspase-3 is not added to the cleavage assay ([Figure 5b](#fig5){ref-type="fig"}, lanes 1--6).

Caspase-3 cleavage inactivates hnRNP K as a DICE-binding protein
----------------------------------------------------------------

The RNA binding activity of hnRNP K, which is conferred by KH domain 3 that interacts with the 3′UTR DICE of the r15-LOX mRNA^[@bib5]^ is critical for its function in translational regulation in erythroid differentiation. To prove that deletion of KH domain 3 by Caspase-3 results in loss of interaction with the target mRNA sequence, *in vitro* RNA binding assays were performed. His-hnRNP K(wt) and His-hnRNP K(1--334) were incubated with a 5′tobramycin (Tob) aptamer bearing DICE or the β-globin mRNA 5′leader as a control transcript (ctrl) bound to a Tob-matrix ([Figure 6](#fig6){ref-type="fig"}). His-hnRNP K(wt) is specifically bound to the DICE RNA, but not to the control RNA ([Figure 6](#fig6){ref-type="fig"}, lanes 1--4). In contrast, binding of truncated His-hnRNP K(1--334) to the DICE RNA is strongly reduced and comparable to the non-specific control RNA, due to the loss of the KH domain 3 that mediates RNA binding specificity ([Figure 6](#fig6){ref-type="fig"}, lanes 5--8). *In vitro* cleavage assays in the presence of the DICE or ctrl RNA showed that RNA binding neither affects His-hnRNP K cleavage by recombinant Caspase-3 ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}), nor that of endogenous hnRNP K in cytoplasmic extract from non-induced K562 cells by recombinant Caspase-3 ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}).

Discussion
==========

In this study, we show that hnRNP K is a Caspase-3 substrate, which is cleaved during erythroid differentiation and puromycin-induced apoptosis of K562 cells. It was known before that the level of hnRNP K decreases during erythroid differentiation^[@bib9]^ and employing hnRNP K immunoprecipitation we detected a specific cleavage product of about 48 kD ([Figure 1a](#fig1){ref-type="fig"}). Previously it was shown that hnRNP K^[@bib10]^ and also other RNA binding proteins as HuR are degraded by the ubiquitin proteasome system^[@bib26]^ in response to genotoxic stress. In DNA damage response, the function of hnRNP K in p53 activation has been reported to be modulated by sumoylation, which enables the protein to function as p53 cofactor^[@bib27]^ or prevents HDM2-dependent ubiquitination and proteasomal degradation of hnRNP K.^[@bib28]^ For YB-1 an ubiquitin and ATP independent cleavage by the 20S proteasome in response to DNA damage was shown,^[@bib29]^ which generates a stable N-terminal fragment accumulating in the nucleus of stressed cells. Therefore we investigated a potential contribution of the ubiquitin proteasome system to hnRNP K degradation. Treatment of K562 cells with the proteasome inhibitor MG132 does not result in a stabilization of hnRNP K ([Figures 3d and e](#fig3){ref-type="fig"}), but even induced cleavage, presumably due to apoptosis induction.^[@bib23]^ Additionally, we performed ubiquitin pull-down assays, but could not detect ubiquitination of hnRNP K during erythroid differentiation. In contrast, ubiquitination of Tak1^[@bib30]^ and XIAP^[@bib31]^ was detectable ([Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). The simultaneous knockdown of the two ubiquitin activating enzymes Uba1^[@bib32]^ and Uba6^[@bib33],\ [@bib34]^ combined with either puromycin treatment or erythroid differentiation did not result in a stabilization of hnRNP K ([Supplementary Figures S7 and S8](#sup1){ref-type="supplementary-material"}), indicating that the ubiquitin proteasome system does not initiate hnRNP K degradation. To identify the so far unknown protease we characterized the hnRNP K-derived fragment. Our analysis indicated that the remaining stable N-terminal fragment lacks KH domain 3 ([Figures 1c and d](#fig1){ref-type="fig"}) that mediates binding to the DICE.^[@bib5]^

Several reports described an activation of Caspase-3 during erythroid differentiation.^[@bib12],\ [@bib13],\ [@bib14]^ Caspase-3 activation was also detectable during sodium-butyrate induced erythroid differentiation of K562 cells ([Figures 2a and b](#fig2){ref-type="fig"}). Cell viability is not influenced by sodium-butyrate treatment^[@bib9]^ and an induction of apoptosis could be excluded by AnnexinV staining ([Figure 2c](#fig2){ref-type="fig"}).

The knockdown of Caspase-3 in puromycin-treated K562 cells showed that cleavage of hnRNP K is impaired *in vivo* and *in vitro* ([Figures 3a--c](#fig3){ref-type="fig"}). The combination of erythroid differentiation with Caspase-3 knockdown had no effect on hnRNP K degradation (not shown). This may be due to the fact that during erythroid differentiation a smaller fraction of Caspase-3 is activated than in puromycin-treated cells ([Figure 2a](#fig2){ref-type="fig"}). The inhibition of Caspase-3 with a specific peptide based inhibitor resulted in a stabilization of hnRNP K in K562 cells ([Figures 3d--e](#fig3){ref-type="fig"}), indicating that Caspase-3 has a function in hnRNP K degradation.

To further elucidate hnRNP K cleavage, we made use of Caspase-3 deficient MCF-7 cells and MCF-7 cells stably transfected with Caspase-3 cDNA^[@bib24]^ ([Figure 4](#fig4){ref-type="fig"}). Analysis of puromycin-induced apoptosis in these cells revealed that hnRNP K is only cleaved in MCF-7(Caspase-3) cells but not MCF-7(pcDNA3.1) cells, ([Figure 4a](#fig4){ref-type="fig"}) strongly indicating that hnRNP K is a Caspase-3 substrate.

Mutational analysis implied that Caspase-3 cleaves hnRNP K C-terminal to D334 ([Figure 5a](#fig5){ref-type="fig"}) and recognizes the favored D-x-x-D-G motif.^[@bib35]^ The minor cleavage products detected in ([Figure 1c](#fig1){ref-type="fig"}) might result from cleavage at position D282--M283. However, D334 seems to represent the major cleavage site of Caspase-3 in hnRNP K, because G335 is strongly favored in P~1~′ position compared with M283.^[@bib35]^ The smaller fragments were only detectable after enrichment by hnRNP K immunoprecipitation ([Figure 1c](#fig1){ref-type="fig"}). *In vitro* cleavage reactions employing recombinant activated Caspase-3 excluded cleavage by an unknown protease, which is activated by Caspase-3 ([Figure 5b](#fig5){ref-type="fig"}). A comparison of the RNA binding capacity of His-hnRNP K(wt) and the N-terminal 48 kD fragment His-hnRNP K(1--334) revealed that the 48 kD fragment lost its specific DICE-binding activity ([Figure 6](#fig6){ref-type="fig"}). Binding to RNA does not influence hnRNP K cleavage *in vitro*. The DICE does not affect the Caspase-3 catalyzed cleavage of His-hnRNP K(wt) ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}) or of endogenous hnRNP K in cytoplasmic K562 cell extract ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}).

The identification of the specific 48 kD hnRNP K fragment and mutational analysis of putative Caspase recognition sites prove that Caspase-3 mediated cleavage separates the C-terminal KH domain 3 of hnRNP K that confers binding specificity to the r15-LOX mRNA DICE^[@bib5]^ from the N-terminal part, which bears protein-interaction sites like the kinase binding domain.^[@bib16],\ [@bib17]^ Site-specific cleavage of hnRNP K represents a second molecular switch besides c-Src dependent Y458 phosphorylation, which modulates mRNA interaction specifically.^[@bib4],\ [@bib5]^ Both, phosphorylation of Y458 in KH domain 3 of hnRNP K that abrogates DICE-binding^[@bib5]^ and the separation from the N-terminus, which confers protein-protein interactions, contribute to the release of r15-LOX mRNA from the translational repressed state.

Analysis of XIAP expression ([Figure 2a](#fig2){ref-type="fig"}) suggests that the activity of Caspase-3 is regulated by XIAP during erythroid differentiation.

Activation of Caspase-3 is well studied in apoptosis where it results in cleavage of multiple proteins.^[@bib11]^ Several reports also suggest a role for Caspase-3 activation in proliferation and differentiation processes in erythroid cells,^[@bib12]^ lens fiber cells,^[@bib36]^ neuronal cells,^[@bib37]^ skeletal muscle cells^[@bib38]^ and in monocyte to macrophage differentiation.^[@bib39],\ [@bib40]^ There Caspase-3 catalyzes the cleavage of a more restricted and distinct set of proteins.^[@bib18]^ Common characteristics of erythropoiesis and the differentiation of lens fiber cells are the exclusion of the nucleus and degradation of other organelles such as mitochondria. R15-LOX initiates the degradation of mitochondria in mature reticulocytes and during lens fiber cell differentiation.^[@bib41]^ The restricted expression of r15-LOX to late differentiation stages and activation of Caspase-3 suggests that r15-LOX expression is regulated by similar mechanisms in these differentiation processes.

Recently, it was reported that Granzyme M cleaves hnRNP K at multiple sites in human cytomegalovirus infection.^[@bib42]^ The fragment of hnRNP K that is generated by Granzyme M in infected cells has a similar molecular weight as the Caspase-3 cleavage product in erythroid differentiation, but cleavage at amino acids D331 or D334 was not detected, instead M359 was mapped as cleavage site.^[@bib42]^

In future studies, it would be interesting to analyze whether cleavage and inactivation of the translational regulator hnRNP K by Caspase-3 is restricted to the hematopoietic lineage or represents a more general mechanism in development and differentiation.

Materials and Methods
=====================

Plasmids
--------

pET16b-hnRNP K^[@bib7]^ was used to generate amino acid substitutions D331E, D334E, D342E, D346E and D350E by site-directed mutagenesis with the following primers:

D331E fw: GGAGACCTGGAGAGCGTTACGACGGCATGG

D331E rv: CCATGCCGTCGTAACGCTCTCCAGGTCTCC

D334E fw: GAGACCGTTACGAGGGCATGGTTGGTTTCA

D334E rv: TGAAACCAACCATGCCCTCGTAACGGTCTC

D342E fw: GTTTCAGTGCTGAAGAAACTTGGGACTCTG

D342E rv: CAGAGTCCCAAGTTTCTTCAGCACTGAAAC

D346E fw:GATGAAACTTGGGAGTCTGCAATAGATACATGG

D346E rv: CCATGTATCTATTGCAGACTCCCAAGTTTCATC

D350E fw: GACTCTGCAATAGAAACATGGAGCCCATCA

D350E rv: TGATGGGCTCCATGTTTCTATTGCAGAGTC

To generate pET16b-hnRNP K(1-334) the nucleotides that encode amino acids 1--334 of human hnRNP K were amplified from pET16b-hnRNP K^[@bib7]^ with the following primers K1--334 BamHI fw: GATAGGAGGATCCGATGGAAACTGAACAGCCAGA, K1--334 BamHI rv: CTATCGGATCCTCTTAGTCGTAACGGTCTCCAGG and cloned into the *Bam*HI site of pET16b. To generate Tob-ctrl, the β-globin 5′leader^[@bib43]^ was cloned into *Xho*I/*Spe*I of pBSIIKS(+) containing the Tob aptamer in the *Kpn*I site (pKS-Tob). pBSIISK-10R^[@bib44]^ was digested with NotI and ligated to an oligo encoding the Tob aptamer: Tob NotI fw: GGCCGCGGCTTAGTATAGCGAGGTTTAGCTACACTCGTGCTGAGCCACTGGGCCAGTGC, Tob NotI rv: GGCCGCACTGGCCCAGTGGCTCAGCACGAGTGTAGCTAAACCTCGCTATACTAAGCCGC.

Cell culture
------------

K562 cells were cultured and induced for erythroid differentiation with 1.5 mℳ sodium butyrate.^[@bib9]^ MCF-7 cells stably transfected with pcDNA3.1 or pcDNA3.1-Caspase-3 were described previously.^[@bib24]^ K562 (1 × 10^5^/ml) and MCF-7 cells were treated with 5 μg/ml puromycin (Sigma-Aldrich, St Luis, MO, USA) for 16 or 24 h. To purify the hnRNP K-derived fragment, K562 cells (3.5 × 10^5^/ml) were treated for 16 h with puromycin (20 μg/ml). Where indicated, the Caspase-3 specific inhibitor Ac-DMQD-CHO (Enzo Life Sciences, Farmingdale, NY, USA) was added to a final concentration of 2 or 10 μℳ. The proteasome inhibitor MG132 (Biomol, Humburg, Germany) was used at 1 μℳ final concentration.

Cytoplasmic extract preparation
-------------------------------

K562 cytoplasmic extracts were generated as described previously.^[@bib9]^

Lysate preparation and western blotting
---------------------------------------

Lysates were prepared and analyzed by western blotting according to A Ostareck-Lederer *et al.*^[@bib4]^

Antibodies
----------

Antibodies were purchased from Santa Cruz (Dallas, TX, USA) (hnRNP K \#1, Caspase-3, Caspase-7, His), Abcam (Cambridge, UK) (GAPDH) and Cell signaling (Cell Signaling, Boston, MA, USA) (PARP, XIAP).

The monoclonal hnRNP K antibody \#2 was generated against a human hnRNP K peptide (~255~MRGRGGFDRMPPGRGGRP~272~),^[@bib9]^ polyclonal hnRNP K antibody \#3 was described.^[@bib45]^

hnRNP K immunoprecipitation
---------------------------

HnRNP K was immunoprecipitated essentially as in IS Naarmann *et al.*^[@bib9]^

HnRNP K fragment purification and mass spectrometry analysis
------------------------------------------------------------

Purification of the hnRNP K-derived fragment is described in the [Supplementary Methods](#sup1){ref-type="supplementary-material"}.

The fragment was excised from a colloidal Coomassie stained NuPAGE 4%--12% Bis-Tris gel (Invitrogen, Carlsbad, CA, USA), *in gel* digested with trypsin, extracted^[@bib46]^ and peptides were analyzed in a capillary HPLC coupled electrospray ionization quadrupole time of flight (ESI-Q-TOF, Ultima, Waters, Milford, MA, USA) mass spectrometer as described.^[@bib47]^ Peptide assignments and data analysis were performed by Mascot, Matrix Science (London, UK).

Caspase-3/7 activity assay
--------------------------

Caspase-3/7 activity was measured using the Caspase-3/7 Glo Assay (Promega) with either 2 × 10^4^ cells ([Figure 2b](#fig2){ref-type="fig"}) or 2 *μ*g lysate ([Figures 3b](#fig3){ref-type="fig"} and [4b](#fig4){ref-type="fig"}). Reactions were spiked with DMSO or the Caspase-3 specific inhibitor Ac-DMQD-CHO at a final concentration of 2 μℳ and 10 *μ*ℳ. Measurements were done in triplicate. The mean of three biological replicates is shown.

AnnexinV and propidium iodide staining
--------------------------------------

For AnnexinV and propidium iodide staining the AnnexinV-FITC Apoptosis Detection Kit I (BD Biosciences, San Jose, CA, USA) was employed. Flow cytometric analysis was performed on a FACS Canto II (BD Biosciences), data were analyzed using Flowjo (Tree Star, Ashland, OR, USA).

RNAi
----

For RNAi K562 cells were transfected with two individual Caspase-3 siRNAs (Casp-3 \#1: GCAGCAAACCUCAGGGAAAdTdT, Casp-3 \#2: AGUGAAGCAAAUCAGAAACdTdT) or a non-specific control siRNA (ctrl) as described previously.^[@bib9]^ Transfection was repeated after 24 h to ensure prolonged Caspase-3 knockdown.

Expression of recombinant hnRNP K
---------------------------------

His-hnRNP K and variants were expressed and purified as described,^[@bib5],\ [@bib7]^ except that proteins were dialyzed against 20 mℳ Tris pH 8.0, 300 mℳ potassium chloride, 10 mℳ sodium citrate and 10% sucrose.

*In vitro* cleavage assay
-------------------------

Five hundred nanograms His-hnRNP K(wt) or variants were incubated with 40-μg cytoplasmic extract from puromycin-treated K562 cells for 16 h, 37 °C in hnRNP K ipp buffer.^[@bib9]^ Reactions were stopped by SDS sample buffer addition and analyzed in western blot assays with a His-tag antibody. Reactions containing 0, 1 or 2 μl of activated recombinant Caspase-3 (Enzo Life Sciences) were incubated accordingly. Where indicated, 500 ng *in vitro* transcribed DICE or control RNA (ctrl)^[@bib47]^ were added to the assays.

*In vitro* transcription
------------------------

RNAs used for affinity purification and in the *in vitro* cleavage assay were transcribed with T3 or T7 MEGAscript Kit (Applied Biosystems, Foster City, CA, USA), respectively.

RNA affinity purification
-------------------------

Tob aptamer RNA affinity purification^[@bib48]^ was modified: Recombinant His-hnRNP K(wt) or His-hnRNP K(1-334) (40 pmol) were incubated with 2 pmol of *in vitro* transcribed RNAs as indicated in BB (20 mℳ Tris-HCl, pH 8.0, 1 mℳ CaCl~2~, 60 mℳ KCl, 3.5 mℳ MgCl~2~, 0.05% NP-40, 0.2 mℳ DTT) for 10 min at room temperature before immobilization at the Tob-matrix (1.5 h, 4 °C). Beads were washed three times with BB and complexes were eluted with SDS sample buffer and subjected to western blotting.
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![hnRNP K is degraded *via* an N-terminal fragment of 48 kD during induced erythroid differentiation and puromycin-induced apoptosis of K562 cells. (**a**) Detection of hnRNP K in cytoplasmic extract (CX) and immunoprecipitates (immunoprecipitation with hnRNP K antibody \#1, Ipp) from K562 cells induced for erythroid differentiation with sodium butyrate for up to 8 days in western blot assays. GAPDH was detected as loading control. (**b**) Detection of hnRNP K and GAPDH in lysates of K562 cells, which were non-treated or treated with puromycin for 16 or 24 h, respectively. (**c**) Immunoprecipitation of hnRNP K with antibody \#1 from cytoplasmic extracts of non-treated K562 cells (lanes 1, 4 and 7), cells induced with sodium butyrate for 2 days (Lanes 2, 5 and 8) or cells treated with puromycin for 16 h (lanes 3, 6 and 9). Western blot analysis of the input and immunoprecipitates with antibodies \#1 (directed against aa 1--121), \#2 (directed against aa 255--272) and \#3 (directed against aa 452--464). (**d**) Amino acid sequence of human hnRNP K. The three KH domains are underlined. Peptides identified in the mass spectrometry analysis after trypsin digestion of the purified N-terminal hnRNP K fragment are shown in bold](cddis201375f1){#fig1}

![Caspase-3 is activated independent of apoptosis induction during erythroid differentiation of K562 cells. (**a**) The expression of Caspase-3, Caspase-7, PARP, XIAP and GAPDH in MCF-7 cells (lane 1) and K562 cells induced for erythroid differentiation for up to 8 days with sodium butyrate (lanes 2--6) or treated with puromycin for 16 h (lane 7) was analyzed in western blots with specific antibodies. (**b**) Caspase-Glo 3/7 assay of K562 cells induced for erythroid differentiation for up to 8 days or treated with puromycin for 16 h. The Caspase-3 inhibitor Ac-DMQD-CHO was added at the final concentration indicated. (**c**) Flow cytometric analysis of an AnnexinV-FITC and propidium iodide staining of K562 cells induced for erythroid differentiation for up to 8 days or treated with puromycin for 16 h](cddis201375f2){#fig2}

![Caspase-3 functions in cleavage of hnRNP K in K562 cells. (**a**) Upper panel: schematic representation of the experiment. K562 cells were transfected with a control siRNA (ctrl) or two individual siRNAs directed against Caspase-3 (Casp \#1, Casp \#2). Twenty-four hours later siRNA transfection was repeated to ensure prolonged knockdown and 5 μg/ml puromycin were added to the cells. Cells were harvested at the indicated time points. Lower panel: western blot analysis of the samples obtained from the experiment described above with antibodies specific for Caspase-3, hnRNP K and GAPDH. (**b**) Left panel: western blot analysis of cytoplasmic extracts generated from cells transfected with ctrl or Casp-3 \#1 siRNA and treated with puromycin for 16 h with Caspase-3 and GAPDH specific antibodies. Right panel: the Caspase-Glo 3/7 assay was performed with extracts characterized at the left. Where indicated Ac-DMQD-CHO was added at a final concentration of 10 μℳ. (**c**) His-hnRNP K was incubated with cytoplasmic extract of ctrl or Casp-3 (\#1) knockdown cells for 16 h at 37 °C. Reactions were stopped by addition of SDS sample buffer and analyzed in western blots with an antibody against the N-terminal His-tag of hnRNP K. GAPDH served as loading control. (**d**) Puromycin treatment of K562 cells was combined with the inhibition of Caspase-3. Cells were either non-treated or treated for 16 and 24 h with 5 μg/ml puromycin. Additionally, Ac-DMQD-CHO was added at the final concentrations indicated. The proteasome inhibitor MG132 was added as a specificity control. Western blot analysis with antibodies against Caspase-3, PARP, hnRNP K and GAPDH. (**e**) The inhibition of Caspase-3 and the proteasome as in (**d**) was combined with the induction of erythroid differentiation by addition of 1.5 mℳ sodium butyrate for up to 2 days. Western blot analysis as in (**d**)](cddis201375f3){#fig3}

![Ectopically expressed Caspase-3 restores hnRNP K cleavage in MCF-7 cells. (**a**) K562 cells, MCF-7 cells transfected with pcDNA3.1 (MCF-7(pcDNA3.1)) or with pcDNA3.1-Caspase-3 (MCF-7(Caspase-3)) were treated with puromycin for 16 and 24 h. Western blot analysis with antibodies directed against Caspase-3, Caspase-7, PARP, hnRNP K, GAPDH. The dotted line indicates extended exposure of the hnRNP K cleavage product. (**b**) Caspase-Glo 3/7 assay of lysates from K562, MCF-7(pcDNA3.1) and MCF-7(Caspase-3) cells treated as in (**a**). Addition of Ac-DMQD-CHO at a final concentration of 10 *μ*ℳ as indicated](cddis201375f4){#fig4}

![Caspase-3 directly cleaves hnRNP K at D334-G335. (**a**) His-hnRNP K(wt) or the variants D331E, D334E, D342E, D346E and D350E were incubated 16 h with cytoplasmic extract from K562 cells treated with 5 μg/ml puromycin for 16 h at 37 °C. Reactions were stopped by addition of SDS sample buffer and analyzed in western blots with antibodies against the His-tag and Caspase-3. (**b**) His-hnRNP K(wt) or His-hnRNP K(D334E) were incubated with different amounts of recombinant Caspase-3 as indicated for 16 h at 37 °C. Analysis as in (**a**)](cddis201375f5){#fig5}

![Caspase-3 cleavage abolishes DICE-binding activity of hnRNP K. Tobramycin RNA affinity purification was performed employing the DICE or the β-globin mRNA 5′leader as control transcript (ctrl) and recombinant His-hnRNP K(wt) or His-hnRNP K(1-334). Western blot analysis with hnRNP K antibody \#1](cddis201375f6){#fig6}
